MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
4.270
+0.310
+7.83%
Pre Market: 4.345 +0.075 +1.74% 08:50 04/01 EDT
OPEN
3.970
PREV CLOSE
3.960
HIGH
4.634
LOW
3.970
VOLUME
1.04K
TURNOVER
0
52 WEEK HIGH
1,299.60
52 WEEK LOW
3.840
MARKET CAP
5.05M
P/E (TTM)
-0.0000
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APVO last week (0323-0327)?
Weekly Report · 2d ago
Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)
TipRanks · 5d ago
Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year
TipRanks · 6d ago
Aptevo Therapeutics sees cash runway into 4Q26
TipRanks · 6d ago
Aptevo Therapeutics GAAP EPS of -$87.27
Seeking Alpha · 6d ago
Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million
Reuters · 6d ago
Aptevo highlights mipletamig AML data showing 79% remission rate
Reuters · 03/23 12:40
Weekly Report: what happened at APVO last week (0316-0320)?
Weekly Report · 03/23 09:14
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.